Companies Haemonetics

Haemonetics

Boston, Massachusetts, USA

1,993 Total Employees

Year Founded: 1971

View Website

Similar Companies Hiring

Babylist

eCommerce • Healthtech • Kids + Family • Retail • Social Media

4 Offices

300 Employees

Aceable

eCommerce • Edtech • Healthtech • Insurance • Mobile • Real Estate • Software

4 Offices

183 Employees

Iodine Software

Artificial Intelligence • Healthtech • Machine Learning • Natural Language Processing • Software

Austin, TX

250 Employees

Haemonetics Company Stability & Growth

Updated on February 06, 2026

This page was generated by Built In using publicly available information and AI-based analysis of common questions about the company. It has not been reviewed or approved by the company.

What's the stability & growth outlook for Haemonetics?

Strengths in profitability, cash generation, and leadership positions in plasma and viscoelastic testing are accompanied by reported revenue pressure and concentration and competitive challenges in select subsegments. Together, these dynamics suggest resilient underlying performance with improving earnings quality while headline growth remains constrained until transition and mix headwinds ease.

Positive Themes About Haemonetics

Profitability: Recent updates show margins and earnings per share improving, with full‑year guidance raised. Management commentary points to stronger operating performance across core Plasma and Blood Management technologies.
Healthy Cash Flow: Guidance indicates higher expected free cash flow and recent quarters delivered notably stronger cash generation. Working capital and margin improvements are contributing to this stability.
Strong Market Position & Advantage: Disclosures describe leadership in plasma collection and advanced viscoelastic testing, reinforced by a large installed base and ongoing product adoption. Strategic acquisitions and upcoming launches are intended to bolster this competitive position.

Considerations About Haemonetics

Stagnant Revenue: Guidance points to a year‑over‑year decline in total reported revenue and recent quarters showed reported contraction. Portfolio divestitures and a major customer transition are masking underlying growth.
Concentrated Customer Base: The impact from a large plasma customer transition highlights exposure to a few significant buyers. Extensions are non‑exclusive and contract shifts can quickly affect reported results.
Weak Market Position & Pricing Challenges: Interventional Technologies has been soft amid adoption shifts and strong incumbent competition, tempering Hospital segment performance. Planned product launches aim to reaccelerate growth, but near‑term momentum remains pressured.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.

View All 48 Jobs at Haemonetics

Is This Your Company? Claim Profile